Fibrinogen and diabetes mellitus: Is it time for intervention trials?

Diabetologia

Volumn 40, Issue 6, 1997, Pages 731-734

  Ceriello, A ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

ATHEROSCLEROSIS; CORONARY RISK; DIABETES MELLITUS; DIABETIC ANGIOPATHY; HUMAN; HYPERCOAGULABILITY; MICROALBUMINURIA; PRIORITY JOURNAL; REVIEW;

ARTERIOSCLEROSIS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FIBRINOGEN; HUMANS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RISK FACTORS; THROMBIN;

EID: 0030818804     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050741     Document Type: Review

References (46)

1. Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118: 956-963
2. Ceriello A (1993) Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36: 1119-1125
3. Christe M, Gattlen P, Fritschi J et al. (1984) The contact phase of blood coagulation in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 52: 221-223
4. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120: 672-676
5. Ganda OP, Arkin CH (1992) Hyperfibrinogenaemia. An important risk factor for vascular complications in diabetes. Diabetes Care 15: 1245-1250
6. Folsom AR, Quamhieh HT, Flack JM (1993) Plasma fibrinogen: levels and correlates in young adults. The coronary artery risk development in young adults (CARDIA) study. Am J Epidemiol 138: 1023-1036
7. El Khawand C, Jamart J, Donckier J et al. (1993) Hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care 16: 1137-1145
8. Dubrey SW, Reaveley DR, Seed M et al. (1994) Risk factors for cardiovascular disease in IDDM: a study of identical twins. Diabetes 43: 831-835
9. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes mellitus. N Engl J Med 310: 356-360
10. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC (1989) Plasma lipid and coagulation factor concentrations in insulin dependent diabetes with microalbuminuria. BMJ 298: 487-490
11. Ceriello A, Taboga C, Giacomello R et al. (1994) Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 43: 430-432
12. Springer TA (1990) Adhesion receptors of the immune system. Nature 346: 425-434
13. Anonymous Editorial (1992) Atherosclerosis goes to the wall. Lancet 2: 647-648
14. Languino RL, Plescia J, Duperray A et al. (1993) Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 73: 1423-1434
15. Blann AD, McCollum CN (1994) Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis. Thromb Haemost 72: 151-154
16. Sugama Y, Tiruppathi C, Janakidevi K, Andersen TT, Fenton JW, Malik AB (1992) Thrombin-induced expression of endothelial P-selectin and intercellular adhesion molecule-1: a mechanism for stabilizing neutrophil adhesion. J Cell Biol 119: 935-944
17. Ceriello A, Falleti E, Giacomello R et al. (1995) Evidence for a correlationship between coagulation activation and adhesion molecule ICAM-1 increase in diabetes. Diabetes 44: 636 (Abstract)
18. Coller BS, Frank RN, Milton RC, Gralmick HR (1978) Plasma cofactors of platelet function: correlation with diabetic retinopathy and hemoglobin A1a-c. Studies in diabetic patients and normal persons. Ann Intern Med 88: 311-316
19. Dalsgaard-Nielsen J, Madsbad S, Hilsted J (1982) Changes in platelet function, blood coagulation and fibrinolysis during insulin-induced hypoglycaemia in juvenile diabetics and normal subjects. Thromb Haemost 47: 254-258
20. Bahru Y, Kesteven P, Alberti KGMM, Walker M (1993) Decreased plasminogen activator inhibitor-1 activity in newly diagnosed type 2 diabetic patients following dietary modification. Diabetic Med 10: 802-806
21. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Proidl S, Prager R, Vukovich T (1994) Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost 71: 692-697
22. Jones RL, Jovanovic L, Forman S, Peterson CM (1984) Time course of reversibility of accelerated fibrinogen disappearance in diabetes mellitus: association with intravascular volume shifts. Blood 63: 22-30
23. Jones RL, Peterson CM (1979) Reduced fibrinogen survival in diabetes mellitus a reversible phenomenon. J Clin Invest 63: 485-493
24. Juhan-Vague I, Thompson SG, Jespersen J (1993) Involvement of the hemostatic system in the insulin resistance syndrome - a study of 1500 patients with angina pectoris. Arteriosclerosis and Thrombosis 13: 1865-1873
25. Cigolini M, Targher G, Desandre G, Muggeo M, Seidell JC (1994) Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. Eur J Clin Invest 24: 126-130
26. Spodick DH (1985) Inflammation and the onset of myocardial infarction. Ann Intern Med 102: 699-702
27. Clerc G (1991) Atherosclerosis as an immune disease? Med Hypotheses 36: 24-26
28. Ceriello A, Quatraro A, Giugliano D (1992) New insights on non-enzymatic glycosylation may lead to therapeutic approaches for the prevention of diabetic complications. Diabet Med 9: 297-299
29. Ceriello A, Pirisi M (1995) Is oxidative stress the missing link between insulin resistance and atherosclerosis? Diabetologia 38: 1484-1485 (Letter)
30. Giugliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19: 257-267
31. Collier A, Rumley AG, Paterson JR, Leach JP, Lowe GDO, Small M (1992) Free radical activity and hemostatic factor in NIDDM patients with and without microalbuminuria. Diabetes 41: 909-913
32. Knobl P, Schernthaner G, Schack C et al. (1993) Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 1045-1050
33. Ceriello A, Pirisi M, Giacomello R et al. (1994) Fibrinogen plasma levels as a marker of thrombin activation: new insights of the role of fibrinogen as a cardiovascular risk factor. Thromb Haemost 71: 593-595
34. Giansante C, Fiotti N, Cattin L, Da Col PG, Calabrese S (1994) Fibrinogen, D-dimer and thrombin-antithrombin complexes in a random population sample: relationships with other cardiovascular risk factors. Thromb Haemostas 71: 581-586
35. Ceriello A, Giacomello R, Stel G et al. (1995) Hyperglycaemia-induced thrombin formation in diabetes: the possible role of oxidative stress. Diabetes 44: 924-928
36. Chantarangkul V, Tripodi A, Mannucci PM (1994) Results of a collaborative study for fibrinogen measurement. Evidence that the use of a common calibrator improves interlaboratory agreement. Blood Coagul Fibrinolysis 5: 761-766
37. Ernst E, Matrai A (1987) Abstention from chronic cigarette smoking normalises blood rheology. Atherosclerosis 64: 75-77
38. Ernst E (1993) Regular exercise reduces fibrinogen levels: a review of longitudinal studies. Br J Sports Med 27: 175-176
39. Hornsby WG, Boggess KA, Lyons TJ, Barnwell WH, Lazarchick J, Colwell JA (1990) Hemostatic alterations with exercise conditioning in NIDDM. Diabetes Care 13: 87-90
40. Engelberg H (1991) Low-dose intermittent heparin therapy decreases plasma fibrinogen levels. Semin Thromb Hemost 17 [Suppl 2]: 219-223
41. Melandri G, Semprini F, Cervi V et al. (1993) Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial. Circulation 88: 2517-2523
42. Ceriello A, Quatraro A, Ettorre M, Marchi E, Barbanti M, Giugliano D (1993) Glucosaminoglycans administration decreases high fibrinogen plasma levels in diabetic patients. Diab Clin Nutr Metab 6: 203-206
43. Ceriello A (1994) Macromolecular protein complex: a new way to understand the fibrinogen lowering effect of glucosaminoglycans? Thromb Haemost 72: 985-986
44. Ernst E (1992) Lowering fibrinogen therapeutically. In: Ernst E, Koening W, Lowe GDO, Meade TW (eds) Fibrinogen: a "new" cardiovascular risk factor. Blackwell-MZV, Wien, pp358-361
45. Winocour PH, Durrington PN, Bhatnagar D (1990) Double blind placebo-controlled study of the effects of bezafibrate on blood lipids, lipoproteins and fibrinogen in hyperlipidaemic type I diabetes mellitus. Diabet Med 7: 736-743
46. Niort G, Cavallero G, Cassader M et al. (1995) The use of bezafibrate in the reduction of lipid and pro-thrombotic cardiovascular risk factors in non-insulin dependent diabetes mellitus. Diab Nutr Metab 8: 226-233